Assessment of tumour hypoxia for prediction of response to therapy and cancer prognosis

Journal of Cellular and Molecular Medicine

Volumn 14, Issue 1-2, 2010, Pages 18-29

  Jubb, Adrian M ^a   Buffa, Francesca M ^a   Harris, Adrian L ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Cancer; Hypoxia; Microarray; Pathology; Prognosis

Indexed keywords

CARBONATE DEHYDRATASE; HYPOXIA INDUCIBLE FACTOR 1ALPHA; MICRORNA; TUMOR MARKER;

CELL HYPOXIA; GENE EXPRESSION PROFILING; GENETICS; HUMAN; KAPLAN MEIER METHOD; METABOLISM; NECROSIS; NEOPLASM; PATHOLOGY; PROGNOSIS; REVIEW; TREATMENT OUTCOME;

CARBONIC ANHYDRASES; CELL HYPOXIA; GENE EXPRESSION PROFILING; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; KAPLAN-MEIER ESTIMATE; MICRORNAS; NECROSIS; NEOPLASMS; PROGNOSIS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 77952107920     PISSN: 15821838     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1582-4934.2009.00944.x     Document Type: Review

References (115)

1. Buccheri G, Ferrigno D. Prognostic value of stage grouping and TNM descriptors in lung cancer. Chest. 2000, 117:1247-55.
2. Rizk NP, Venkatraman E, Bains MS. American Joint Committee on Cancer staging system does not accurately predict survival in patients receiving multimodality therapy for esophageal adenocarcinoma. J Clin Oncol. 2007, 25:507-12.
3. Roldo C, Missiaglia E, Hagan JP. MicroRNA expression abnormalities in pancreatic endocrine and acinar tumors are associated with distinctive pathologic features and clinical behavior. J Clin Oncol. 2006, 24:4677-84.
4. Tomlinson R, Gray L. The histological structure of some lung cancers and the possible implications for radiotherapy. Br J Cancer. 1955, 9:539-49.
5. Almog N, Ma L, Raychowdhury R. Transcriptional switch of dormant tumors to fast-growing angiogenic phenotype. Cancer Res. 2009, 69:836-44.
6. Zhang X, Gaspard JP, Chung DC. Regulation of vascular endothelial growth factor by the Wnt and K-ras pathways in colonic neoplasia. Cancer Res. 2001, 61:6050-4.
7. Petit AM, Rak J, Hung MC. Neutralizing antibodies against epidermal growth factor and ErbB-2 neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: angiogenic implications for signal transduction therapy of solid tumors. Am J Pathol. 1997, 151:1523-30.
8. Casanova ML, Larcher F, Casanova B. A critical role for ras-mediated, epidermal growth factor receptor-dependent angiogenesis in mouse skin carcinogenesis. Cancer Res. 2002, 62:3402-7.
9. Rak J, Mitsuhashi Y, Bayko L. Mutant ras oncogenes upregulate VEGF VPF expression: implications for induction and inhibition of tumor angiogenesis. Cancer Res. 1995, 55:4575-80.
10. Mizukami Y, Li J, Zhang X. Hypoxia-inducible factor-1-independent regulation of vascular endothelial growth factor by hypoxia in colon cancer. Cancer Res. 2004, 64:1765-72.
11. Blancher C, Moore JW, Talks KL. Relationship of hypoxia-inducible factor (HIF)-1alpha and HIF-2alpha expression to vascular endothelial growth factor induction and hypoxia survival in human breast cancer cell lines. Cancer Res. 2000, 60:7106-13.
12. Liu Y, Cox SR, Morita T. Hypoxia regulates vascular endothelial growth factor gene expression in endothelial cells. Identification of a 5′ enhancer. Circ Res. 1995, 77:638-43.
13. Ryan HE, Lo J, Johnson RS. HIF-1 alpha is required for solid tumor formation and embryonic vascularization. EMBO J. 1998, 17:3005-15.
14. Shweiki D, Itin A, Soffer D. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature. 1992, 359:843-5.
15. Maxwell PH, Dachs GU, Gleadle JM. Hypoxia-inducible factor-1 modulates gene expression in solid tumors and influences both angiogenesis and tumor growth. Proc Natl Acad Sci USA. 1997, 94:8104-9.
16. Skinner SA, Frydman GM, O'Brien PE. Microvascular structure of benign and malignant tumors of the colon in humans. Dig Dis Sci. 1995, 40:373-84.
17. Brown JM, Giaccia AJ. The unique physiology of solid tumors: opportunities (and problems) for cancer therapy. Cancer Res. 1998, 58:1408-16.
18. Li C, Wright MM, Jackson RM. Reactive species mediated injury of human lung epithelial cells after hypoxia-reoxygenation. Exp Lung Res. 2002, 28:373-89.
19. Harris AL. Hypoxia-a key regulatory factor in tumour growth. Nat Rev Cancer. 2002, 2:38-47.
20. Anderson AR, Weaver AM, Cummings PT. Tumor morphology and phenotypic evolution driven by selective pressure from the microenvironment. Cell. 2006, 127:905-15.
21. Graeber TG, Osmanian C, Jacks T. Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours. Nature. 1996, 379:88-91.
22. Kim CY, Tsai MH, Osmanian C. Selection of human cervical epithelial cells that possess reduced apoptotic potential to low-oxygen conditions. Cancer Res. 1997, 57:4200-4.
23. Kondo A, Safaei R, Mishima M. Hypoxia-induced enrichment and mutagenesis of cells that have lost DNA mismatch repair. Cancer Res. 2001, 61:7603-7.
24. Kim KJ, Li B, Winer J. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature. 1993, 362:841-4.
25. Claffey KP, Brown LF, del Aguila LF. Expression of vascular permeability factor vascular endothelial growth factor by melanoma cells increases tumor growth, angiogenesis, and experimental metastasis. Cancer Res. 1996, 56:172-81.
26. Wouters BG, Brown JM. Cells at intermediate oxygen levels can be more important than the " hypoxic fraction" in determining tumor response to fractionated radiotherapy. Radiat Res. 1997, 147:541-50.
27. Kaanders JH, Wijffels KI, Marres HA. Pimonidazole binding and tumor vascularity predict for treatment outcome in head and neck cancer. Cancer Res. 2002, 62:7066-74.
28. Kaanders JH, Pop LA, Marres HA. ARCON: experience in 215 patients with advanced head-and-neck cancer. Int J Radiat Oncol Biol Phys. 2002, 52:769-78.
29. Overgaard J, Hansen HS, Overgaard M. A randomized double-blind phase III study of nimorazole as a hypoxic radiosensitizer of primary radiotherapy in supraglottic larynx and pharynx carcinoma. Results of the Danish Head and Neck Cancer Study (DAHANCA) Protocol 5-85. Radiother Oncol. 1998, 46:135-46.
30. Overgaard J, Eriksen JG, Nordsmark M. Plasma osteopontin, hypoxia, and response to the hypoxia sensitiser nimorazole in radiotherapy of head and neck cancer: results from the DAHANCA 5 randomised double-blind placebo-controlled trial. Lancet Oncol. 2005, 6:757-64.
31. Rischin D, Hicks RJ, Fisher R. Prognostic significance of 18F-misonidazole positron emission tomography-detected tumor hypoxia in patients with advanced head and neck cancer randomly assigned to chemoradiation with or without tirapazamine: a substudy of Trans-Tasman Radiation Oncology Group Study 98.02. J Clin Oncol. 2006, 24:2098-104.
32. Scott EN, Meinhardt G, Jacques C. Vatalanib: the clinical development of a tyrosine kinase inhibitor of angiogenesis in solid tumours. Expert Opin Investig Drugs. 2007, 16:367-79.
33. Vaupel P, Mayer A. Hypoxia in cancer: significance and impact on clinical outcome. Cancer Metastasis Rev. 2007, 26:225-39.
34. Hockel M, Vaupel P. Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects. J Natl Cancer Inst. 2001, 93:266-76.
35. Hockel M, Knoop C, Schlenger K. Intratumoral pO2 predicts survival in advanced cancer of the uterine cervix. Radiother Oncol. 1993, 26:45-50.
36. Gatenby RA, Kessler HB, Rosenblum JS. Oxygen distribution in squamous cell carcinoma metastases and its relationship to outcome of radiation therapy. Int J Radiat Oncol Biol Phys. 1988, 14:831-8.
37. Fyles A, Milosevic M, Hedley D. Tumor hypoxia has independent predictor impact only in patients with node-negative cervix cancer. J Clin Oncol. 2002, 20:680-7.
38. Hockel M, Schlenger K, Aral B. Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix. Cancer Res. 1996, 56:4509-15.
39. Hockel M, Schlenger K, Hockel S. Hypoxic cervical cancers with low apoptotic index are highly aggressive. Cancer Res. 1999, 59:4525-8.
40. Knocke TH, Weitmann HD, Feldmann HJ. Intratumoral pO2-measurements as predictive assay in the treatment of carcinoma of the uterine cervix. Radiother Oncol. 1999, 53:99-104.
41. Lyng H, Sundfor K, Trope C. Disease control of uterine cervical cancer: relationships to tumor oxygen tension, vascular density, cell density, and frequency of mitosis and apoptosis measured before treatment and during radiotherapy. Clin Cancer Res. 2000, 6:1104-12.
42. Nordsmark M, Loncaster J, Aquino-Parsons C. The prognostic value of pimonidazole and tumour pO2 in human cervix carcinomas after radiation therapy: a prospective international multi-center study. Radiother Oncol. 2006, 80:123-31.
43. Colpaert CG, Vermeulen PB, Fox SB. The presence of a fibrotic focus in invasive breast carcinoma correlates with the expression of carbonic anhydrase IX and is a marker of hypoxia and poor prognosis. Breast Cancer Res Treat. 2003, 81:137-47.
44. Couvelard A, O'Toole D, Leek R. Expression of hypoxia-inducible factors is correlated with the presence of a fibrotic focus and angiogenesis in pancreatic ductal adenocarcinomas. Histopathology. 2005, 46:668-76.
45. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000, 100:57-70.
46. Christofori G, Naik P, Hanahan D. A second signal supplied by insulin-like growth factor II in oncogene-induced tumorigenesis. Nature. 1994, 369:414-8.
47. Feldser D, Agani F, Iyer NV. Reciprocal positive regulation of hypoxia-inducible factor 1alpha and insulin-like growth factor 2. Cancer Res. 1999, 59:3915-8.
48. Dong Z, Venkatachalam MA, Wang J. Up-regulation of apoptosis inhibitory protein IAP-2 by hypoxia. Hif-1-independent mechanisms. J Biol Chem. 2001, 276:18702-9.
49. Seimiya H, Tanji M, Oh-hara T. Hypoxia up-regulates telomerase activity via mitogen-activated protein kinase signaling in human solid tumor cells. Biochem Biophys Res Commun. 1999, 260:365-70.
50. Rofstad EK, Mathiesen B, Kindem K, Galappathi K. Acidic extracellular pH promotes experimental metastasis of human melanoma cells in athymic nude mice. Cancer Res. 2006, 66:6699-707.
51. Swietach P, Wigfield S, Cobden P. Tumor-associated carbonic anhydrase 9 spatially coordinates intracellular pH in three-dimensional multicellular growths. J Biol Chem. 2008, 283:20473-83.
52. Erler JT, Bennewith KL, Cox TR. Hypoxia-induced lysyl oxidase is a critical mediator of bone marrow cell recruitment to form the premetastatic niche. Cancer Cell. 2009, 15:35-44.
53. Erler JT, Bennewith KL, Nicolau M. Lysyl oxidase is essential for hypoxia-induced metastasis. Nature. 2006, 440:1222-6.
54. Mole DR, Blancher C, Copley RR. Genome-wide association of hypoxia-inducible factor (HIF)-1 alpha and HIF-2 alpha DNA binding with expression profiling of hypoxia-inducible transcripts. J Biol Chem. 2009, 284:16767-75.
55. Kim W. The VHL tumor suppressor protein, HIF and cancer. J Cell Mol Med. 2009
56. Boyd JM, Gallo GJ, Elangovan B. Bik, a novel death-inducing protein shares a distinct sequence motif with Bcl-2 family proteins and interacts with viral and cellular survival-promoting proteins. Oncogene. 1995, 11:1921-8.
57. Koong AC, Denko NC, Hudson KM. Candidate genes for the hypoxic tumor phenotype. Cancer Res. 2000, 60:883-7.
58. Ivanova AV, Ivanov SV, Danilkovitch-Miagkova A. Regulation of STRA13 by the von Hippel-Lindau tumor suppressor protein, hypoxia, and the UBC9 ubiquitin proteasome degradation pathway. J Biol Chem. 2001, 276:15306-15.
59. Nishiwaki T, Daigo Y, Kawasoe T. Isolation and mutational analysis of a novel human cDNA, DEC1 (deleted in esophageal cancer 1), derived from the tumor suppressor locus in 9q32. Genes Chromosomes Cancer. 2000, 27:169-76.
60. Chi JT, Wang Z, Nuyten DS. Gene expression programs in response to hypoxia: cell type specificity and prognostic significance in human cancers. PLoS Med. 2006, 3:395-409.
61. Kim SJ, Rabbani ZN, Vollmer RT. Carbonic anhydrase IX in early-stage non-small cell lung cancer. Clin Cancer Res. 2004, 10:7925-33.
62. Couvelard A, O'Toole D, Turley H. Microvascular density and hypoxia-inducible factor pathway in pancreatic endocrine tumours: negative correlation of microvascular density and VEGF expression with tumour progression. Br J Cancer. 2005, 92:94-101.
63. Loncaster JA, Harris AL, Davidson SE. Carbonic anhydrase (CA IX) expression, a potential new intrinsic marker of hypoxia: correlations with tumor oxygen measurements and prognosis in locally advanced carcinoma of the cervix. Cancer Res. 2001, 61:6394-9.
64. Sowter HM, Raval RR, Moore JW. Predominant role of hypoxia-inducible transcription factor (Hif)-1alpha versus Hif-2alpha in regulation of the transcriptional response to hypoxia. Cancer Res. 2003, 63:6130-4.
65. Chen C, Pore N, Behrooz A. Regulation of glut1 mRNA by hypoxia-inducible factor-1. Interaction between H-ras and hypoxia. J Biol Chem. 2001, 276:9519-25.
66. Hu CJ, Wang LY, Chodosh LA. Differential roles of hypoxia-inducible factor 1alpha (HIF-1alpha) and HIF-2alpha in hypoxic gene regulation. Mol Cell Biol. 2003, 23:9361-74.
67. Dales JP, Garcia S, Meunier-Carpentier S. Overexpression of hypoxia-inducible factor HIF-1alpha predicts early relapse in breast cancer: retrospective study in a series of 745 patients. Int J Cancer. 2005, 116:734-9.
68. Generali D, Berruti A, Brizzi MP. Hypoxia-inducible factor-1alpha expression predicts a poor response to primary chemoendocrine therapy and disease-free survival in primary human breast cancer. Clin Cancer Res. 2006, 12:4562-8.
69. Yamamoto Y, Ibusuki M, Okumura Y. Hypoxia-inducible factor 1alpha is closely linked to an aggressive phenotype in breast cancer. Breast Cancer Res Treat. 2008, 110:465-75.
70. Trastour C, Benizri E, Ettore F. HIF-1alpha and CA IX staining in invasive breast carcinomas: prognosis and treatment outcome. Int J Cancer. 2007, 120:1451-8.
71. Bos R, van der Groep P, Greijer AE. Levels of hypoxia-inducible factor-1alpha independently predict prognosis in patients with lymph node negative breast carcinoma. Cancer. 2003, 97:1573-81.
72. Schindl M, Schoppmann SF, Samonigg H. Overexpression of hypoxia-inducible factor 1alpha is associated with an unfavorable prognosis in lymph node-positive breast cancer. Clin Cancer Res. 2002, 8:1831-7.
73. Helczynska K, Larsson AM, Holmquist Mengelbier L. Hypoxia-inducible factor-2alpha correlates to distant recurrence and poor outcome in invasive breast cancer. Cancer Res. 2008, 68:9212-20.
74. Gruber G, Greiner RH, Hlushchuk R. Hypoxia-inducible factor 1 alpha in high-risk breast cancer: an independent prognostic parameter. Breast Cancer Res. 2004, 6:R191-8.
75. Chen G, Ray R, Dubik D. The E1B 19K Bcl-2-binding protein Nip3 is a dimeric mitochondrial protein that activates apoptosis. J Exp Med. 1997, 186:1975-83.
76. Tan EY, Campo L, Han C. BNIP3 as a progression marker in primary human breast cancer; opposing functions in in situ versus invasive cancer. Clin Cancer Res. 2007, 13:467-74.
77. Hutchison GJ, Valentine HR, Loncaster JA. Hypoxia-inducible factor 1alpha expression as an intrinsic marker of hypoxia: correlation with tumor oxygen, pimonidazole measurements, and outcome in locally advanced carcinoma of the cervix. Clin Cancer Res. 2004, 10:8405-12.
78. Liao D, Corle C, Seagroves TN. Hypoxia-inducible factor-1alpha is a key regulator of metastasis in a transgenic model of cancer initiation and progression. Cancer Res. 2007, 67:563-72.
79. Rofstad EK, Galappathi K, Mathiesen B. Fluctuating and diffusion-limited hypoxia in hypoxia-induced metastasis. Clin Cancer Res. 2007, 13:1971-8.
80. Ginouves A, Ilc K, Macias N. PHDs overactivation during chronic hypoxia " desensitizes" HIFalpha and protects cells from necrosis. Proc Natl Acad Sci USA. 2008, 105:4745-50.
81. Martinive P, Defresne F, Bouzin C. Preconditioning of the tumor vasculature and tumor cells by intermittent hypoxia: implications for anticancer therapies. Cancer Res. 2006, 66:11736-44.
82. Willam C, Warnecke C, Schefold JC. Inconsistent effects of acidosis on HIF-alpha protein and its target genes. Pflugers Arch. 2006, 451:534-43.
83. Iakovlev VV, Pintilie M, Morrison A. Effect of distributional heterogeneity on the analysis of tumor hypoxia based on carbonic anhydrase IX. Lab Invest. 2007, 87:1206-17.
84. Vleugel MM, Greijer AE, Shvarts A. Differential prognostic impact of hypoxia induced and diffuse HIF-1alpha expression in invasive breast cancer. J Clin Pathol. 2005, 58:172-7.
85. Li YM, Zhou BP, Deng J. A hypoxia-independent hypoxia-inducible factor-1 activation pathway induced by phosphatidylinositol-3 kinase Akt in HER2 overexpressing cells. Cancer Res. 2005, 65:3257-63.
86. Wykoff CC, Beasley NJ, Watson PH. Hypoxia-inducible expression of tumor-associated carbonic anhydrases. Cancer Res. 2000, 60:7075-83.
87. Winter SC, Shah KA, Han C. The relation between hypoxia-inducible factor (HIF)-1alpha and HIF-2alpha expression with anemia and outcome in surgically treated head and neck cancer. Cancer. 2006, 107:757-66.
88. Kaluz S, Kaluzova M, Chrastina A. Lowered oxygen tension induces expression of the hypoxia marker MN carbonic anhydrase IX in the absence of hypoxia-inducible factor 1 alpha stabilization: a role for phosphatidylinositol 3'-kinase. Cancer Res. 2002, 62:4469-77.
89. Nordsmark M, Eriksen JG, Gebski V. Differential risk assessments from five hypoxia specific assays: the basis for biologically adapted individualized radiotherapy in advanced head and neck cancer patients. Radiother Oncol. 2007, 83:389-97.
90. Sobhanifar S, Aquino-Parsons C, Stanbridge EJ. Reduced expression of hypoxia-inducible factor-1alpha in perinecrotic regions of solid tumors. Cancer Res. 2005, 65:7259-66.
91. Ord JJ, Agrawal S, Thamboo TP. An investigation into the prognostic significance of necrosis and hypoxia in high grade and invasive bladder cancer. J Urol. 2007, 178:677-82.
92. McShane LM, Altman DG, Sauerbrei W. REporting recommendations for tumour MARKer prognostic studies (REMARK). Br J Cancer. 2005, 93:387-91.
93. van de Vijver MJ, He YD, van't Veer LJ. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med. 2002, 347:1999-2009.
94. Wang Y, Klijn JG, Zhang Y. Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet. 2005, 365:671-9.
95. Seigneuric R, Starmans MH, Fung G. Impact of supervised gene signatures of early hypoxia on patient survival. Radiother Oncol. 2007, 83:374-82.
96. Zhang C, Kawauchi J, Adachi MT. Activation of JNK and transcriptional repressor ATF3 LRF1 through the IRE1 TRAF2 pathway is implicated in human vascular endothelial cell death by homocysteine. Biochem Biophys Res Commun. 2001, 289:718-24.
97. Kitamuro T, Takahashi K, Ogawa K. Bach1 functions as a hypoxia-inducible repressor for the heme oxygenase-1 gene in human cells. J Biol Chem. 2003, 278:9125-33.
98. Nuyten DS, Kreike B, Hart AA. Predicting a local recurrence after breast-conserving therapy by gene expression profiling. Breast Cancer Res. 2006, 8:R62.
99. Chen JL, Lucas JE, Schroeder T. The genomic analysis of lactic acidosis and acidosis response in human cancers. PLoS Genet. 2008, 4:e1000293.
100. Winter SC, Buffa FM, Silva P. Relation of a hypoxia metagene derived from head and neck cancer to prognosis of multiple cancers. Cancer Res. 2007, 67:3441-9.
101. Hurwitz H, Fehrenbacher L, Novotny W. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004, 350:2335-42.
102. Murat A, Migliavacca E, Hussain SF. Modulation of angiogenic and inflammatory response in glioblastoma by hypoxia. PLoS One. 2009, 4:e5947.
103. Walsh S, Gill C, O'Neill A. Hypoxia increases normal prostate epithelial cell resistance to receptor-mediated apoptosis via AKT activation. Int J Cancer. 2009, 124:1871-8.
104. Calin GA, Croce CM. MicroRNA signatures in human cancers. Nat Rev Cancer. 2006, 6:857-66.
105. Camps C, Buffa FM, Colella S. hsa-miR-210 Is induced by hypoxia and is an independent prognostic factor in breast cancer. Clin Cancer Res. 2008, 14:1340-8.
106. Kulshreshtha R, Ferracin M, Wojcik SE. A microRNA signature of hypoxia. Mol Cell Biol. 2007, 27:1859-67.
107. Brazma A, Hingamp P, Quackenbush J. Minimum information about a microarray experiment (MIAME)-toward standards for microarray data. Nat Genet. 2001, 29:365-71.
108. Shi L, Reid LH, Jones WD. The MicroArray Quality Control (MAQC) project shows inter- and intraplatform reproducibility of gene expression measurements. Nat Biotechnol. 2006, 24:1151-61.
109. Moeller BJ, Richardson RA, Dewhirst MW. Hypoxia and radiotherapy: opportunities for improved outcomes in cancer treatment. Cancer Metastasis Rev. 2007, 26:241-8.
110. Williams KJ, Telfer BA, Xenaki D. Enhanced response to radiotherapy in tumours deficient in the function of hypoxia-inducible factor-1. Radiother Oncol. 2005, 75:89-98.
111. Dische S, Saunders M, Barrett A. A randomised multicentre trial of CHART versus conventional radiotherapy in head and neck cancer. Radiother Oncol. 1997, 44:123-36.
112. Koukourakis MI, Bentzen SM, Giatromanolaki A. Endogenous markers of two separate hypoxia response pathways (hypoxia inducible factor 2 alpha and carbonic anhydrase 9) are associated with radiotherapy failure in head and neck cancer patients recruited in the CHART randomized trial. J Clin Oncol. 2006, 24:727-35.
113. Zhu Y, Denhardt DT, Cao H. Hypoxia upregulates osteopontin expression in NIH-3T3 cells via a Ras-activated enhancer. Oncogene. 2005, 24:6555-63.
114. Fyfe GA, Hurwitz H, Fehrenbacher L. Bevacizumab plus irinotecan 5-FU leucovorin for treatment of metastatic colorectal cancer results in survival benefit in all pre-specified patient subgroups. J Clin Oncol. 2004, 22:3617.
115. Minn H, Gronroos TJ, Komar G. Imaging of tumor hypoxia to predict treatment sensitivity. Curr Pharm Des. 2008, 14:2932-42.